A phase II trial of BST-204 in patients with cancer induced muscle loss (cancer cachexia)
Phase of Trial: Phase II
Latest Information Update: 02 Jan 2018
Price : $35 *
At a glance
- Drugs BST-204 (Primary)
- Indications Cachexia
- Focus Proof of concept; Therapeutic Use
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 27 Dec 2017 New trial record
- 20 Dec 2017 According to a Green Cross media release, the company expects to initiate this study prior to the end of the first quarter 2018.